Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
CA 2430702 C · Owner: Vazquez Blomquist, Dania M. · Inventors: Iglesias Perez, Enrique; Vazquez Blomquist, Dania M.; Duarte Cano, Carlos A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to HIV chimeric genes formed by the union of fragments of different genes of said virus, wherein said fragments contain epitopes for cytotoxic T cells (CTL) or HIV-1 auxiliary T cells which are presented by a , wide range of antigens of type 1 Major Human Histocompatibility System (HLA- 1). Recombinant poxvirus are obtained from said genes which are useful for , prophylactic and therapeutic vaccination against HIV/AIDS infection are , capable of generating a protective immune cell response in vaccinated laboratory animals and are recognized by the CTL lymphocytes of HIV/AIDS patients.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 22, 2002 and granted July 9, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 22, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 22, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.